Ocuphire Pharma Inc/ US67577R1023 /
5/24/2024 8:47:56 PM | Chg. +0.04 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
1.75USD | +2.34% | 700 Turnover: 1,204 |
-Bid Size: - | -Ask Size: - | 1.75 | 1.71 |
GlobeNewswire
5/10
Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update
GlobeNewswire
4/11
First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS...
GlobeNewswire
4/1
Ocuphire Announces the U.S. Commercial Launch of RYZUMVl™ (Phentolamine Ophthalmic Solution 0.75%) b...
GlobeNewswire
3/8
Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corpo...
GlobeNewswire
2/5
Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degener...
GlobeNewswire
1/4
Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of...
GlobeNewswire
11/30/2023
Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII
GlobeNewswire
11/27/2023
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
11/27/2023
Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
GlobeNewswire
11/13/2023
Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update
GlobeNewswire
11/2/2023
Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Re...
GlobeNewswire
11/1/2023
Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
11/1/2023
Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Offi...
GlobeNewswire
10/6/2023
Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October
GlobeNewswire
9/27/2023
Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.7...
GlobeNewswire
9/11/2023
Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences
GlobeNewswire
9/7/2023
Ocuphire Pharma to Present at ESCRS 2023 and MODLive! Conferences in September